Elite in Chronic Obstructive Pulmonary Disease (COPD)

Henrik Watz

Ahrensburg, SH, DE 
Elite in Chronic Obstructive Pulmonary Disease (COPD)
Ahrensburg, SH, DE 
OverviewLocationsClinical Research

Overview

Henrik Watz practices in Ahrensburg, Germany. Mr. Watz is rated as an Elite expert by MediFind in the treatment of Chronic Obstructive Pulmonary Disease (COPD). His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Asthma, Eosinophilic Pneumonia, and Simple Pulmonary Eosinophilia.

His clinical research consists of co-authoring 235 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 188 articles and participated in 2 clinical trials in the study of Chronic Obstructive Pulmonary Disease (COPD).

Gender
Male

Locations

Ahrensburg, SH, Germany
Other Locations
Grosshansdorf, SH, Germany
Luebeck, SH, Germany
Schleswig, SH, Germany
Giessen, HE, Germany
Hannover, NI, Germany
Munich, BY, Germany
Heidelberg, BW, Germany
Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks (With a 48-week Safety Subset) in Subjects With Moderate to Severe COPD
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ensifentrine Over 24 Weeks (With a 48-week Safety Subset) in Subjects With Moderate to Severe COPD
Enrollment Status: Completed
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Ensifentrine
Study Phase: Phase 3
A Randomized, Double-blind (Sponsor Unblind), Placebo-controlled, Multi-centred Phase IIa Study to Evaluate the Safety and Efficacy of 13 Weeks of Once Daily Oral Dosing of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Older Men and Post Menopausal Women With COPD and Muscle Weakness, Participating in Home Exercise
A Randomized, Double-blind (Sponsor Unblind), Placebo-controlled, Multi-centred Phase IIa Study to Evaluate the Safety and Efficacy of 13 Weeks of Once Daily Oral Dosing of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Older Men and Post Menopausal Women With COPD and Muscle Weakness, Participating in Home Exercise
Enrollment Status: Completed
Publish Date: July 15, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 1 Less Clinical Trial

235 Total Publications

High Oscillometry-derived Airway Resistance Is Associated with FEV1 Decline and Future Abnormal Spirometry in Smokers with Initially Normal Spirometry.
High Oscillometry-derived Airway Resistance Is Associated with FEV1 Decline and Future Abnormal Spirometry in Smokers with Initially Normal Spirometry.
Journal: American journal of respiratory and critical care medicine
Published: September 12, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Watz's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile